( March 14, 2025, 9:42 AM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on March 13 held that a biopharmaceutical patent holder was entitled to a patent term extension (PTE) for a reissued patent, disagreeing with arguments from generic drug manufacturers about how the U.S. Patent and Trademark Office (PTO) calculated the date for patent reissuance....